Related Experiment Video

Updated: Jul 24, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms

Anne S Reiner1, Benjamin H Durham2,3, Mariko Yabe2

  • 1Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

British Journal of Haematology
|July 3, 2023
PubMed

Insights

Targeted therapy interruption for histiocytic neoplasms often leads to relapse. However, achieving complete response, having non-BRAFV600E mutations, or MEK-only inhibition may improve outcomes.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Outcomes after interrupting targeted therapy for histiocytic neoplasms are poorly understood.
  • Histiocytic neoplasms are rare and require effective treatment strategies.

Purpose of the Study:

  • To investigate disease relapse and survival following interruption of BRAF and MEK inhibitors in adult patients with histiocytic neoplasms.
  • To identify factors associated with improved relapse-free survival after treatment cessation.

Main Methods:

  • Retrospective study of 22 adult patients with histiocytic neoplasms.
  • Treatment interruption occurred after achieving complete or partial response assessed by 18-fluorodeoxyglucose positron emission tomography (FDG-PET).
  • Analysis of relapse-free survival based on response, mutation status, and treatment received.

Main Results:

  • Disease relapse occurred in 17/22 (77%) of patients after treatment interruption.
  • Complete response before interruption, non-BRAFV600E mutations, and MEK inhibition alone were linked to significantly better relapse-free survival.
  • Limited-duration targeted therapy may be feasible for select patients.

Conclusions:

  • Relapse is a frequent event after discontinuing targeted therapy for histiocytic neoplasms.
  • Patient-specific factors and treatment regimens influence the likelihood of sustained remission.
  • Further research is needed to optimize treatment duration and management strategies.
Keywords:
MAPK pathwaygene targetinghistiocytosismyeloproliferative disordertargeted therapy

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

508
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573